Phillips-Medisize Opens Design and Development Center in China
News Jun 05, 2015
Phillips-Medisize Corporation has announced the opening of its new design and development center in Suzhou, China. Growth of the company’s design and development centers supports its customers’ needs for patient-administered biologics and pharmaceutical drug delivery and diagnostics device design and development services.
The creation of this new design and development center is in keeping with Phillips-Medisize’s long standing global strategy of providing both regional manufacturing and outsourced design/development support for its global customers.
Outsourced design and development services has proven to be important to the company’s customer base as it provides common worldwide quality standards and design controls while allowing for local service and manufacturing support.
As part of the company’s network of design and development centers, the Suzhou facility has multiple capabilities including device design, injection molding simulation, developmental tooling and assembly equipment, along with on-site program management. This design and development group is actively working on multiple projects, including biologics drug delivery devices intended specifically for Asian markets.
In commenting on this new addition, Matt Jennings, Chairman and CEO of Phillips-Medisize Corporation said, “This is a very exciting time for our customers and our company. The new Suzhou design and development center, as part of our network, will support our customers’ need for outsourced design and develop of new market appropriate products for the Asian market."
The company’s network of four (4) design centers located in North America, Europe and now Asia, employ approximately 200 engineering professionals, while the global program management and new product introduction teams of 275 engineering professionals successfully drove the launch of 81 new products in 2014.
Traditionally, over 80% of the new drug delivery, diagnostic, and med-tech products the company launches have their roots within the Phillips-Medisize design and development organization.
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE